# DESI2

## Overview
DESI2 is a gene that encodes the protein desumoylating isopeptidase 2, which is a member of the DESI family of proteins characterized by the presence of a conserved PPPDE peptidase domain. This protein functions as a desumoylating enzyme, playing a critical role in the removal of small ubiquitin-like modifier (SUMO) proteins from target proteins, a process known as desumoylation. This post-translational modification is essential for regulating various cellular processes, including nuclear transport, transcriptional regulation, and DNA repair. Desumoylating isopeptidase 2 is primarily localized at the Golgi apparatus in human cells, where it contributes to protein homeostasis and cellular function. It is also involved in the regulation of the AKT/mTOR signaling pathway, which is important for cell growth and survival, and has been implicated in embryonic development and apoptosis (Ou2018Desumoylating; Shen2014High).

## Function
DESI2, also known as desumoylating isopeptidase 2, is involved in the process of desumoylation, which is the removal of small ubiquitin-like modifier (SUMO) proteins from target proteins. This post-translational modification is crucial for regulating various cellular processes, including nuclear transport, transcriptional regulation, and DNA repair. DESI2 is part of the DESI family, which includes proteins with a highly conserved PPPDE peptidase domain, indicating its role in protein stability and gene transcription (Shen2014High).

In healthy human cells, DESI2 is ubiquitously distributed and primarily located at the Golgi apparatus, suggesting its involvement in maintaining protein homeostasis and cellular function (Shen2014High). The protein's activity is crucial for regulating the phosphorylation status of the AKT/mTOR signaling pathway, which is important for cell growth and survival (Ou2018Desumoylating). DESI2 has been implicated in embryonic development and apoptosis, although its precise functions in these processes remain to be fully elucidated (Shen2014High). The enzyme's role in desumoylation highlights its importance in maintaining cellular function and stability.

## Clinical Significance
The DESI2 gene, encoding desumoylating isopeptidase 2, plays a significant role in the regulation of pancreatic cancer cell proliferation and apoptosis. Alterations in DESI2 expression have been linked to changes in the PI3K/AKT/mTOR signaling pathway, which is crucial for cell growth and survival. In pancreatic cancer cell lines, silencing DESI2 results in increased cell proliferation and decreased apoptosis, while overexpression leads to reduced proliferation and enhanced apoptosis. These findings suggest that DESI2 may have antitumor activity by inhibiting the PI3K/AKT/mTOR pathway, highlighting its potential as a therapeutic target in pancreatic cancer treatment (Ou2018Desumoylating).

Despite its potential clinical significance in cancer, there is limited information on specific diseases or conditions directly resulting from mutations in the DESI2 gene. The gene is mentioned in the context of the 1q43q44 deletion, but no specific diseases or conditions associated with DESI2 mutations or alterations are detailed (Rooney2022DNA). Further research is needed to fully understand the clinical implications of DESI2 in other diseases.


## References


[1. (Ou2018Desumoylating) Xi Ou, Guang-tao Zhang, Zhe Xu, Jing-sen Chen, Yong Xie, Ji-Kui Liu, and Xiao-Ping Liu. Desumoylating isopeptidase 2 (desi2) inhibits proliferation and promotes apoptosis of pancreatic cancer cells through regulating pi3k/akt/mtor signaling pathway. Pathology &amp; Oncology Research, 25(2):635–646, November 2018. URL: http://dx.doi.org/10.1007/s12253-018-0487-4, doi:10.1007/s12253-018-0487-4. This article has 3 citations.](https://doi.org/10.1007/s12253-018-0487-4)

[2. (Shen2014High) Cong-Cong Shen, Xin-Yi Cui, Yi He, Yu-Huan Kang, Cheng Yi, Jin-Liang Yang, and Lan-Tu Gou. High phosphorylation status of akt/mtor signal in desi2-reduced pancreatic ductal adenocarcinoma. Pathology &amp; Oncology Research, 21(2):267–272, July 2014. URL: http://dx.doi.org/10.1007/s12253-014-9817-3, doi:10.1007/s12253-014-9817-3. This article has 4 citations.](https://doi.org/10.1007/s12253-014-9817-3)

[3. (Rooney2022DNA) Kathleen Rooney and Bekim Sadikovic. Dna methylation episignatures in neurodevelopmental disorders associated with large structural copy number variants: clinical implications. International Journal of Molecular Sciences, 23(14):7862, July 2022. URL: http://dx.doi.org/10.3390/ijms23147862, doi:10.3390/ijms23147862. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23147862)